share_log

Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target

Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target

Needham重申買入Cartesian Therapeutics,維持42美元的目標股價
Benzinga ·  05/08 11:40

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.

Needham分析師吉爾·布魯姆重申Cartesian Therapeutics(納斯達克股票代碼:RNAC)的買入並維持42美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論